The implementation of immune checkpoint inhibitors (ICIs), with or without chemotherapy, as
first-line treatment for patients who do not have actionable mutations has proved to be a …

In the latest years, some drugs have been approved by European Medicines Agency (EMA)
and/or the US Food and Drug Administration (FDA) for the treatment of patients with …

Immune checkpoint blockades (ICBs) have changed the standard of care of squamous and
adenocarcinoma non‐small cell lung cancer (NSCLC). Whereas detailed researches …

Objective: Lymphatic metastasis is one of the leading causes of malignancy dispersion in
various types of cancer. However, few anti-lymphangiogenic drugs have been approved for …

Lung cancer poses a serious threat to human health. Although targeted therapies have led
to breakthroughs in the treatment of lung cancer, drug resistance and side effects limit their …

The human body and its microbiome constitute a highly delicate system. The gut microbiome
participates in the absorption of the host's nutrients and metabolism, maintains the …

Purpose Anlotinib protects against carcinogenesis through the induction of autophagy and
apoptosis. The current study evaluated the role and molecular mechanisms of anlotinib in …

Objectives Combined therapy should be invested for those patients who are refractory to first-
line therapy. Anti-angiogenic agents could enhance tumor immunity response. We designed …

Background Cadonilimab is a bispecific antibody that simultaneously targets programmed
cell death receptor-1 and cytotoxic T lymphocyte-associated antigen-4. This study aimed to …

Non-small cell lung cancer (NSCLC) is the malignant tumor with the highest morbidity and
leading cause of death worldwide, whereas its pathogenesis has not been fully elucidated …